Risks and Safe Dosing of Intravenous Iron in Dialysis Patients

Dose‑Dependent Toxicity

In hemodialysis patients receiving chronic IV iron, monthly doses > 200 mg are linked to a six‑fold increase in acute cardiocerebrovascular events (HR ≈ 6.0) and nearly three‑fold higher hospitalization rates (HR ≈ 2.8) over a 2‑year follow‑up【1】.
Monthly IV iron of 300–399 mg raises adjusted mortality by ~13 % (HR ≈ 1.13), while doses ≥ 400 mg/month increase mortality by ~18 % (HR ≈ 1.18) in large international observational cohorts【1】.
Cumulative exposure of 840–1 600 mg over six months triples the risk of death (HR ≈ 3.1) and multiplies cardiovascular events by 3.5‑fold compared with lower cumulative doses【1】.
Cumulative exposure of 1 640–2 400 mg over six months further escalates mortality (HR ≈ 3.7) and cardiovascular events (HR ≈ 5.1)【1】.
Short‑term studies (≤ 3 months) do not show these harms, whereas studies with 1–2 year follow‑up consistently demonstrate increased mortality and cardiovascular events, indicating a chronic cumulative toxicity rather than an acute effect【1】.

Elevated hepcidin‑25 levels caused by iron overload correlate with both fatal and non‑fatal cardiovascular events【2】.
Iron infusions induce fibroblast growth factor‑23 (FGF‑23), which exerts direct cardiotoxic effects【2】.
Non‑transferrin‑bound iron generates oxidative stress that impairs endothelial function and accelerates atherosclerosis【2】.
Myocardial iron deposition observed in heavily overloaded patients may contribute to sudden cardiac death, based on pre‑ESA era autopsy data【2】.

Low‑dose IV iron (≤ 200 mg/month) increases infection risk by ~1.8‑fold, while high‑dose (> 200 mg/month) raises infection risk by > 5‑fold【1】.
Iron overload leads to immune dysfunction, including CD4⁺ T‑cell depletion, reduced phagocytic activity, and enhanced bacterial virulence due to increased iron availability【2】.
Bolus dosing of 700 mg monthly carries a higher short‑term infection risk than a maintenance regimen of 200 mg/month【1】.

Hepcidin dysregulation serves as a physiological defense against iron overload but becomes pathologically elevated with chronic excess【2】.
Oxidative stress from iron overload induces pancreatic β‑cell apoptosis, potentially worsening glycemic control【2】.
Diabetic dialysis patients experience amplified diabetic complications when exposed to excess iron【2】.

Ferritin concentrations between 300–800 ng/mL are common and generally not linked to adverse outcomes; however, persistently > 800 ng/mL warrants closer monitoring and possible dose reduction【3】.
Ferritin consistently > 100 µg/L (as observed in Japanese cohorts) is associated with a 2.2‑fold higher risk of acute cardiocerebrovascular disease, a 1.8‑fold higher infection risk, and a 2.3‑fold higher mortality risk【1】.
Ferritin > 1 000 ng/mL should be avoided chronically【3】.
Transferrin saturation (TSAT) > 50 % is a more sensitive indicator of problematic iron loading than ferritin alone and should prompt reconsideration of therapy【3】.

Acute infusion reactions (e.g., anaphylaxis, hypotension, chest pain) occur in < 1 % of administrations and manifest during or immediately after the infusion【3】.
Sub‑acute infectious complications typically emerge within weeks to months after high‑dose regimens【1】.
Chronic cardiovascular events and excess mortality become evident after 1–2 years of sustained excessive dosing【1】.

Patients with diabetes constitute ~40 % of the dialysis population and have a heightened susceptibility to macro‑ and micro‑vascular complications when exposed to excess iron【2】.
Individuals with extensive atherosclerotic disease experience accelerated cardiovascular events under high‑iron exposure【2】.
Young dialysis patients with repeated graft failures accumulate decades of iron burden, increasing long‑term toxicity risk【2】.
Patients with active severe infection should not receive IV iron, as it can exacerbate infection outcomes【4】.

Limit maintenance IV iron to ≤ 200 mg per month to avoid the dose‑related rise in infection and cardiovascular risk【1】.
For hemodialysis patients, an initial repletion regimen of 100–125 mg weekly for 8–10 doses followed by a maintenance dose of 25–125 mg weekly is appropriate【5】.
Avoid bolus monthly doses of 700 mg; divided smaller doses are associated with lower infection risk【1】.
Withhold iron therapy when ferritin exceeds 800 ng/mL or when TSAT exceeds 50 %【3】【5】.

Extrapolating safety data from short‑term (< 3 months) studies to long‑term practice overlooks cumulative toxicity that appears after 1–2 years【1】.
Relying solely on ferritin without assessing TSAT can miss problematic iron loading; TSAT > 50 % should trigger dose reassessment【3】.
Continuing aggressive iron dosing in diabetic patients disregards their amplified risk for cardiovascular and metabolic complications【2】.
Interpreting elevated hepcidin as a pathological barrier rather than a physiological response to overload may lead to inappropriate iron supplementation【2】.